Latest market price
0.61
-0.00-0.02%
LABQT28Standard BioTools Inc.·NASDAQ
0.61-0.02%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E—EPS (ttm)-0.23Insider Own31.01%Shs Outstand392.58MPerf Week1.65%
Market Cap239.43MForward P/E—EPS next Y-0.16Insider Trans0.00%Shs Float42.90MPerf Month-18.10%
Enterprise Value1.46MPEG—EPS next Q-0.02Short Float5.70%Perf Quarter-25.67%
Income-88.00MP/S2.82EPS this Y—Short Ratio1.69Perf Half Y-34.77%
Sales85.00MP/B0.44EPS next Y—ROA-13.93%Short Interest2.45MPerf YTD-52.35%
Book/sh1.38P/C0.50EPS next 5Y—ROE-18.16%52W High1.72 -64.54%Perf Year-46.97%
Cash/sh1.22P/FCF—EPS past 3/5Y—ROIC-8.25%52W Low0.59 3.71%Perf 3Y-69.20%
Dividend Est.—EV/EBITDA0.03Sales past 3/5Y-4.63% -9.24%Gross Margin49.14%Volatility4.58% 6.15%Perf 5Y-88.13%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin-94.80%ATR (14)0.04Perf 10Y-87.87%
Dividend Ex-Date—Quick Ratio8.80Sales Y/Y TTM-36.57%Profit Margin-103.29%RSI (14)38.20Recom2.40
Dividend Gr. 3/5Y—Current Ratio9.10EPS Q/Q—SMA20-5.01%Beta1.53Target Price3.25
Payout0.00%Debt/Eq0.04Sales Q/Q-9.09%SMA50-10.20%Rel Volume1.40Prev Close0.61
Employees387LT Debt/Eq0.04EarningsNov 03SMA200-33.03%Avg Volume1.22MPrice0.61
IPO DateFeb 10, 2011Option/ShortNo / NoEPS/Sales Surpr.-449.02% -3.37%Net Debt/EBITDA—Volume1,708,226Change-0.02%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-27-25DowngradeKeybancOverweight → Sector Weight
Apr-04-24ReiteratedJefferies$3.25
Nov-05-19DowngradeJanney Montgomery ScottBuy → Neutral
Oct-17-19UpgradeUBSNeutral → Buy
Jan-02-19UpgradeJanney Montgomery ScottNeutral → Buy
Nov-01-18UpgradePiper SandlerNeutral → Overweight
Feb-04-16UpgradeMizuhoNeutral → Buy
Jan-19-16DowngradeCowen & Co.Outperform → Market Perform
Nov-01-15UpgradeCantor FitzgeraldHold → Buy
Oct-29-15UpgradeCantor FitzgeraldHold → Buy
Latest News· Times ET
Oct-30-26
Oct-05-26
Sep-30-26
Sep-11-26
Sep-10-26
Sep-08-26
Aug-05-26
Jul-28-26
Jul-22-26
Jul-21-26
Jul-20-26
Company

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue8585174106—————
Cost of Goods Sold Incl. D&A44439056—————
Gross Profit41438450—————
Selling, General and Administrative Excl. Other8611015788—————
Research and Development18266226—————
Other Operating Expense1804013—————
Operating Income-79-93-175-77—————
Interest Expense0035—————
Unusual Expense
—————————
Non-Operating Income (Expense)-10-3407—————
Net Income Before Taxes-91-97-138-74—————
Income Taxes-37-3810—————
Consolidated Net Income-88-75-139-75—————
Net Income From Continuing Operations-55-59-139-75—————
Net Income-88-75-139-75—————
EPS (Recurring)-0.23-0.20-0.52-0.94—————
EPS (Basic, Before Extraordinaries)-0.23-0.20-0.52-0.94—————
EPS (Diluted)-0.23-0.20-0.52-0.94—————
EBITDA-93-86-118-54—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio2.815.753.551.65—————
Gross Margin48.2450.5948.2847.17—————
Operating Margin-92.94-109.41-100.57-72.64—————
Net Margin-103.53-88.24-79.89-70.75—————
Shares Outstanding39138235379—————
Market Capitalization238489618175—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$1.84$1.49$1.14$0.79$0.44● Close Price0.00M3.48M6.97M10.45M13.93MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Egholm MichaelPresident & CEOApr 06 '26Option Exercise0.00196,51306,790,596Apr 08
Kim Hanjoon AlexChief Financial OfficerApr 06 '26Option Exercise0.0070,18302,800,702Apr 08
Casdin Partners Master Fund, L.P.Director, 10% OwnerDec 04 '25Buy1.45150,000217,02072,100,000Dec 04
Casdin Partners Master Fund, L.P.Director, 10% OwnerDec 03 '25Buy1.4475,000108,03771,950,000Dec 04
Casdin Partners Master Fund, L.P.Director, 10% OwnerDec 02 '25Buy1.42125,000177,51371,875,000Dec 04
Casdin Partners Master Fund, L.P.Director, 10% OwnerNov 25 '25Buy1.307,550,0009,838,40571,750,000Nov 26
Casdin Partners Master Fund, L.P.Director, 10% OwnerNov 24 '25Buy1.43150,000214,87564,200,000Nov 26
Casdin Partners Master Fund, L.P.Director, 10% OwnerNov 20 '25Buy1.30450,000586,26064,050,000Nov 20
Casdin Partners Master Fund, L.P.Director, 10% OwnerNov 19 '25Buy1.28350,000448,91063,600,000Nov 20
Casdin Partners Master Fund, L.P.Director, 10% OwnerNov 18 '25Buy1.23275,000339,40563,250,000Nov 20
Casdin Partners Master Fund, L.P.Director, 10% OwnerNov 17 '25Buy1.22225,000275,58062,975,000Nov 17
Casdin Partners Master Fund, L.P.Director, 10% OwnerNov 14 '25Buy1.24250,000309,80062,750,000Nov 17
Casdin Partners Master Fund, L.P.Director, 10% OwnerNov 13 '25Buy1.20450,000541,39562,500,000Nov 17
Casdin Partners Master Fund, L.P.Director, 10% OwnerNov 12 '25Buy1.19375,000445,83862,050,000Nov 12
Casdin Partners Master Fund, L.P.Director, 10% OwnerNov 11 '25Buy1.20300,000358,80061,675,000Nov 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.